Health Authority Meeting Support
How we help with Health Authority Meeting Support
Building a collaborative relationship with the U.S. Food and Drug Administration (FDA) is an essential component of a robust product development strategy for sponsors intending to bring novel drugs, biologics, and/or devices to market. Fortunately, the FDA offers various opportunities for interaction and guidance throughout the development lifecycle. FDA meetings provide an opportunity for sponsors to educate the Agency about their product(s) and the corresponding development strategies.
In turn, these meetings allow sponsors to seek input regarding available data, discuss evolving regulatory requirements, and identify potential gaps in the overall product plan. These interactions are often an invaluable tool for de-risking product development, particularly for sponsors advancing highly complex product modalities and/or pursuing novel therapeutic targets.
We help you prepare for health authority meetings.
Type A: Meetings that are “necessary for an otherwise stalled product development program to proceed (a critical path meeting) or to address an important safety issue.”
Type B PreIND: The purpose is to obtain FDA feedback on the drug development program and de-risk any potential clinical hold issues during the FDA review of the IND.
Type B End of Phase: The purpose is to discuss and de-risk the study design for the next clinical trial and to ensure the CMC and nonclinical aspects of the program are in line with the FDA’s expectations for the next phase of development.
Type C: Considered the “catch-all” category and includes any meeting concerning the development and review of a product that does not fall within the scope of other meeting types.
Type D: New for PDUFA VII – Intended for follow-up on a limited number of topics and are useful for gaining additional clarification or negotiating a particular issue in a development program.
INTERACT: New for CDER for PDUFA VII – Now for both biologics and drugs. Useful for early-stage settings. Typically used for setting nonclinical and early CMC strategies and do not take the place of a
PreIND meeting. Pre-Sub: CDRH meeting that occurs most frequently. Opportunity to obtain FDA feedback before premarket submission and ask product development questions.
Related Services
RELATED INSIGHTS
-
Raw Material Control for Biotechs (Part 2): Clinical Development Considerations
Introduction This is part two of the Halloran Insights article on raw material control. Raw Material Control for Biotechs Part one addressed the importance of establishing a level of raw material control at the earliest stages of product development. This article will focus on maturing the raw material control strategy in preparation for a commercial […]
-
Moving from Discovery to Commercialization in Precision Medicine
The revolution in precision medicine, a form of medicine using information about a person’s own genes or proteins to prevent, diagnose, or treat disease, has reached an exciting phase with the advancement of cell and gene therapies (CGTs). Precision medicine, also known as personalized medicine, is an approach to patient care that enables treatments most […]
-
Rare But Not Forgotten: Opportunities in Rare Disease Drug Development
This article was co-written by Samantha Zappia, Principal Consultant, SK Regulatory Solutions. The World Orphan Drug Congress (WODC) brings together industry leaders working to advance orphan and rare disease drug development in one place for a unique three-day event. Many attendees arrive with the goal of meeting other players in the industry, learning from successes […]